Please assess the completion status of the following clinical trial:

Trial Title: TBI Dose De-escalation for Fanconi Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Meeting the definition of standard risk or high risk Fanconi anemia as defined in the next two sections:~* Standard risk patients must be \<18 years of age with a diagnosis of Fanconi anemia with aplastic anemia (AA), myelodysplastic syndrome without excess blasts, or high risk genotype as defined below:~  * Aplastic anemia is defined as having at least one of the following when not receiving growth factors or transfusions:~    * platelet count \<20 \* 10\^9/L~   * ANC \<5 \* 10\^8/L~   * Hemoglobin \<8 g/dL~ * Myelodysplastic syndrome (MDS) with multilineage dysplasia with or without chromosomal anomalies~ * High risk genotype (e.g. IVS-4 or exon 14 FANCC mutations, or BRCA1 or 2 mutations)~* High risk patients must have one or more of the following high risk features:~  * Advanced MDS (≥ 5% blast) or acute leukemia~ * Require additional HSCT for graft failure~ * History at any time of systemic fungal or gram negative infection~ * Severe renal disease with a creatinine clearance \<40 mL/min~ * Age \> 18 years~* Very high risk patients must have Advanced MDS (≥ 5% blast) or acute leukemia after initial hematopoietic stem cell transplant (HSCT)~* Patients must have an appropriate source of stem cells. Patients and donors will be typed for HLA-A, B, C and DRB1 using high resolution molecular typing.~* Adequate major organ function including:~  * Cardiac: ejection fraction \>45%~ * Hepatic: bilirubin, AST or ALT, ALP \<5 x normal~ * Karnofsky performance status \>70% or Lansky \>50 (if \< 16 years of age)~* Women of child-bearing age must be using adequate birth control and have a negative pregnancy test.~* Written consent.~Exclusion Criteria:~* Available HLA-genotypically identical related donor in standard risk patients.~* Active central nervous system (CNS) leukemia at time of study enrollment.~* History of squamous cell carcinoma of the head/neck/cervix within previous 2 years.~* Prior radiation therapy that prevents further total body irradiation (TBI).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with TBI (Type: EXPERIMENTAL): Patients treated with total body irradiation, Fludarabine, Cyclophosphamide, Bone Marrow Transplantation, Mycophenolate Mofetil, and Sirolimus.

Based on this trial design, predict the completion outcome and termination type (if applicable).